News Corporate Actions Novelix Pharmaceuticals Allots 3,25,000 Equity Shares to Promoter Group MemberNovelix Pharmaceuticals Allots 3,25,000 Equity Shares to Promoter Group Member
Novelix Pharmaceuticals Limited completed a preferential allotment of 3,25,000 equity shares to promoter group member Vupparapalli Pavani on 12th February 2026, representing 1.63% of total share capital. This increased Pavani's shareholding from 4,00,000 shares (2.27%) to 7,25,000 shares (3.64%). The company's equity capital expanded from Rs. 176,150,000 to Rs. 199,350,000, and all regulatory disclosures under SEBI takeover regulations have been filed with BSE Limited.
*this image is generated using AI for illustrative purposes only.
Novelix Pharmaceuticals Limited has announced the completion of a preferential allotment of equity shares to a promoter group member, marking a significant corporate development for the pharmaceutical company. The transaction involves the allotment of 3,25,000 equity shares to Vupparapalli Pavani on 12th February 2026.
Share Allotment Details
The preferential allotment was executed in favor of Vupparapalli Pavani, who belongs to the promoter group category. The allotment details are structured as follows:
| Parameter | Details |
|---|---|
| Allottee Name | Vupparapalli Pavani |
| Category | Promoter Group |
| Shares Allotted | 3,25,000 |
| Percentage of Total Capital | 1.63% |
| Allotment Date | 12th February 2026 |
Shareholding Pattern Changes
The preferential allotment has resulted in significant changes to Pavani's shareholding pattern in the company:
| Shareholding Status | Number of Shares | Percentage (Total Capital) | Percentage (Diluted Capital) |
|---|---|---|---|
| Before Acquisition | 4,00,000 | 2.27% | 1.60% |
| Shares Acquired | 3,25,000 | 1.63% | 1.19% |
| After Acquisition | 7,25,000 | 3.64% | 2.66% |
Capital Structure Impact
The preferential allotment has modified the company's overall capital structure:
| Capital Structure | Amount | Share Details |
|---|---|---|
| Pre-Allotment Equity Capital | Rs. 176,150,000 | 1,76,15,000 shares of Rs. 10 each |
| Post-Allotment Equity Capital | Rs. 199,350,000 | 19,935,000 shares of Rs. 10 each |
| Total Diluted Capital | Rs. 266,850,000 | Including 73,35,000 outstanding convertible warrants |
Regulatory Compliance
The company has fulfilled its regulatory obligations by filing the necessary disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Vupparapalli Pavani submitted her disclosure on 14th February 2026, while the company forwarded the compliance documents to BSE Limited on 17th February 2026.
The transaction was executed through preferential allotment mode, and no encumbrances such as pledges, liens, or non-disposal undertakings are associated with the allotted shares. The company's shares are listed on BSE Limited under the scrip code 536565 and scrip ID NOVELIX.
Historical Stock Returns for Trimurthi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +2.33% | +18.69% | +62.30% | +154.24% | +1,122.96% |
16
